Biogen
NEWS
FUJIFILM Corporation announced that it has completed the acquisition of Biogen Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen.
Biogen and Alkermes announced positive topline data from EVOLVE-MS-2, a Phase III trial of diroximel fumarate for relapsing-remitting multiple sclerosis compared to Tecfidera.
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Skyhawk and Merck will partner to discover and develop innovative RNA-binding small molecules that can form treatments for neurological diseases and cancer.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
Now that Novartis has a competing therapy on the market for spinal muscular atrophy (SMA), Biogen is eager to show why it thinks its Spinraza (nusinersen) is superior.
“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
JOBS
IN THE PRESS